TET2

Genetic findings for TET2 in Systemic Mastocytosis

Variants (1)

VariantTypeFrequencySignificance
Various loss-of-functionsomatic~47% of advanced SMMost frequently mutated gene in advanced SM besides KIT. Epigenetic regulator involved in DNA demethylation. Unlike S/A/R mutations, TET2 mutations do not independently predict inferior survival.

Clinical implications

Various loss-of-function

Common but not high-risk. Part of the multi-mutated landscape of advanced SM.

Also found in: MDS/MPN/AML (~10-30%), Clonal hematopoiesis of indeterminate potential (Common)

Related hypotheses

Hereditary alpha-tryptasemia (HαT) modifies SM phenotype, increasing mediator symptoms and anaphylaxis risk independent of mast cell burden

40
emerging·6 studies

Sources (2)

DetailsJawhar M et al. (2016) Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V+ advanced systemic mastocytosis · LeukemiaDOI
DetailsPardanani A (2021) Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management · Am J HematolDOI